Multi-target design of fused cyclic pyrimidine-2-thione candidates as DNA intercalators and topoisomerase I/II inhibitors
Consequently, the compounds afforded can be regarded as prominent lead anticancer compounds for further optimization and investigation.
Authors
- Galal A. Elsayed (ORCID: https://orcid.org/0000-0002-5542-667X)
- Mohd Ali Hassan (ORCID: https://orcid.org/0000-0001-9509-9266)
- Ahmed A. Al‐Karmalawy (ORCID: https://orcid.org/0000-0002-8173-6073)
- Ayman Abo Elmaaty (ORCID: https://orcid.org/0000-0002-4634-3039)
- M. Khalil
Institutions
- Ain Shams University (EG)
- Damietta University (EG)
- Mashreq University (SD)
- Port Said University (EG)
Publication Details
- Journal
- Future Medicinal Chemistry
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1080/17568919.2025.2602424
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00